Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2025.07.072 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics.
Curr Issues Mol Biol
August 2025
Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by immune dysregulation and epidermal barrier dysfunction. Advances in understanding the interplay of genetic predisposition, cytokine signaling, and environmental triggers have led to the emergence of targeted therapies. Although biologic agents such as dupilumab, tralokinumab, and lebrikizumab have revolutionized AD management, their high costs, injectable administration, and limited global accessibility highlight the need for alternative options.
View Article and Find Full Text PDFFirst Description of Upadacitinib as Treatment for Collagenous Colitis with a Concomitant Lymphocytic Disorder of the Upper Gastrointestinal Tract.
Case Rep Gastroenterol
March 2025
Department of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Introduction: The medical treatment of refractory collagenous colitis with a concomitant symptomatic lymphocytic disorder of the upper gastrointestinal tract is very challenging with scarce evidence.
Case Presentation: We present a 61-year-old female patient with a long-standing highly refractory collagenous colitis with a concomitant symptomatic lymphocytic disorder with villous atrophy and intraepithelial lymphocytes of the upper gastrointestinal tract causing severe watery diarrhoea with severe hypokalemia and recurrent episodes of prerenal kidney injuries requiring several hospital admissions. Celiac serology as well as genetic analyses (HLA-DQ2/DQ8) were negative, and other common etiologies of intraepithelial lymphocytosis and villous atrophy were ruled out.
Angiotensin II-induced phosphorylation of CHK1 at serine-280 drives cardiac remodelling by direct phosphorylation of JAK1, thus activating JAK1-STAT signalling in murine cardiomyocytes.
Br J Pharmacol
August 2025
Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
Background And Purpose: Cardiac remodelling is a common pathological process of heart disease. Checkpoint kinase 1 (CHK1), a key regulator of the DNA damage response and cell cycle, is well-studied in oncology, but its role in pathological cardiac remodelling remains unclear. Here, we investigated the activation of CHK1 and its effects in mouse models of cardiac remodelling induced by angiotensin II.
View Article and Find Full Text PDFThe Role of Upadacitinib in Refractory Dermatomyositis: A Systematic Review.
J Am Acad Dermatol
August 2025
Department of Dermatology, Wayne State University, Detroit, MI, USA.
Upadacitinib for Alopecia: Current Evidence and Clinical Insights.
Skin Appendage Disord
August 2025
Israel Englander Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.
Background: Upadacitinib, a selective Janus kinase (JAK) 1 inhibitor, has demonstrated promising efficacy in alopecia areata (AA), particularly in patients unresponsive to conventional therapies. As JAK inhibitors gain prominence, understanding upadacitinib's role in AA management is critical.
Summary: This scoping review synthesizes data from 24 publications, including 64 AA patients treated with upadacitinib (15-45 mg daily).